CALC · CalciMedica, Inc.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

The securities are held by Bering Partners II, L.P. ("Bering II"). Bering Partners II GP, L.L.C. ("Bering II GP") is the general partner of Bering II and may be deemed to have voting and dispositive power over the securities held by Bering II. The Reporting Person, a member of the Issuer's board of directors, and Philip Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein.

1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

The issue date of the Series A Warrants is August 19, 2026.

The expiration of these Series A Warrants is the earlier of (i) 18 months after the closing date of the Private Placement and (ii) 30 days following the Issuer's public announcement of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

The securities are held by Bering Partners II, L.P. ("Bering II"). Bering Partners II GP, L.L.C. ("Bering II GP") is the general partner of Bering II and may be deemed to have voting and dispositive power over the securities held by Bering II. The Reporting Person, a member of the Issuer's board of directors, and Philip Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein.

The issue date of the Series B Warrants is August 19, 2026.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

1/36th of the shares subject to the option vest in equal monthly installments over a three year period following the date of grant.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI Co-Investment Fund, LP ("SVP VI Co-Investment, LP", together with Sanderling Venture Partners VI, LP., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Securities"). The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

Beginning October 1, 2025, 1/3rd of the shares subject to the option shall vest in equal monthly installments.

The weighted average purchase price for the transaction reported was $2.6779, and the range of prices were between $2.65 and $2.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

The weighted average purchase price for the transaction reported was $3.1488, and the range of prices were between $2.75 and $3.21. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

The weighted average purchase price for the transaction reported was $2.8630, and the range of prices were between $2.75 and $2.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

The weighted average purchase price for the transaction reported was $2.7928, and the range of prices were between $2.75 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

Immediately exercisable.

The weighted average purchase price for the transaction reported was $2.8194, and the range of prices were between $2.74 and $2.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

The weighted average purchase price for the transaction reported was $2.8977, and the range of prices were between $2.80 and $2.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

The weighted average purchase price for the transaction reported was $2.7930, and the range of prices were between $2.70 and $2.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

The weighted average purchase price for the transaction reported was $2.585, and the range of prices were between $2.57 and $2.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

The sale of the common stock of CalciMedica, Inc. (the "Issuer") by the spouse of the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase of 1,000 shares of the Issuer's common stock by the reporting person's spouse at a price of $1.85 per share on July 1, 2025. The reporting person has agreed to pay to the Issuer upon settlement of the sale, $1,799.83, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.

The weighted average purchase price for the transaction reported was $3.3707, and the range of prices were between $3.33 and $3.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

The weighted average purchase price for the transaction reported was $2.4323, and the range of prices were between $2.30 and $2.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.